Income Statement (KEZAR/LIFE)

KEZAR/LIFE NEWS

Q2 EPS Estimate for Kezar Life Sciences Raised by Analyst By MarketBeat - 1 week ago

Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) – Equities researchers at William Blair increased their Q2 2025 EPS estimates for Kezar Life Sciences in a note issued to investors on Tuesday, Ma… [+3273 chars]...

Read more
Renaissance Technologies LLC Lowers Stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) By MarketBeat - 3 weeks ago

Renaissance Technologies LLC lessened its stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) by 93.2% in the 4th quarter, according to its most recent disclosure with the SEC. Th… [+3147 chars]...

Read more
Kezar Life Sciences (KZR) Projected to Post Quarterly Earnings on Thursday By MarketBeat - 3 weeks ago

Kezar Life Sciences (NASDAQ:KZR – Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce ea… [+2038 chars]...

Read more
Geode Capital Management LLC Sells 560,342 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) By MarketBeat - 3 weeks ago

Geode Capital Management LLC lowered its stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) by 89.4% during the 4th quarter, according to the company in its most recent Form 13F … [+3149 chars]...

Read more
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight By DelveInsight - 2 weeks ago

New York, USA, May 13, 2025 (GLOBE NEWSWIRE) -- Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Met… [+17406 chars]...

Read more
Top Stock
CurrencyPrice Chg
BA
208.18 6.68
3.32%
CVX
137.91 1.89
1.39%
CAT
351.79 2.3
0.66%
INTC
20.25 -0.12
-0.59%
MSFT
458.68 1.32
0.29%
DIS
112.02 0.5
0.45%
DOW
28.79 0.45
1.59%
CSCO
63.05 -0.29
-0.46%
GS
604.86 -3.58
-0.59%